Short answer
Wave Life Sciences Ltd. (WVE) filed its Q1 2026 10-Q quarterly report on Apr 28, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $38M (up 316.9% year over year) with net income of −$26M.
Q1 2026 key financials · XBRL
- Revenue
- $38M
- +316.9% YoY
- Net income
- −$26M
- +44.4% YoY
- Operating margin
- -81.8%
- EPS (diluted)
- −$0.13
- +55.2% YoY
Source: XBRL data from the Wave Life Sciences Ltd. (WVE) Q1 2026 10-Q on SEC EDGAR. USD.
Wave Life Sciences Ltd. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided; excerpt contains no material risk disclosures
- New insider-trading disclosure: four directors adopted Rule 10b5-1 plans covering 123,200 ordinary shares
- Potential market-overhang risk: planned sales active through March 5, 2027
- Regulatory compliance disclosure: plans intended to satisfy Rule 10b5-1(c) affirmative-defense conditions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Wave Life Sciences Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.